Ten drugs were classified as low or no added therapeutic benefit compared with alternatives, accounting for $6.7 billion in ...
Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback